A New Target for Brain Tumors: TUG1, the Gene Controlling DNA Replication Stress

Brain tumors, particularly glioblastomas, are among the most difficult cancers to treat. A new study has found that Taurine Upregulated Gene 1 (TUG1) plays a critical role in cancer cells' ability to cope with replication stress. The study could offer a potential treatment strategy against aggressive brain tumors.

Replication is the process of copying or duplicating DNA during cell division. The cell's double-stranded DNA molecule separates, and each strand serves as a template for a new DNA strand. The result is two genetically identical double-stranded DNA molecules. When the cell divides, these are distributed to the two new cells, giving each a complete set of genetic information. Replication is critical for preserving genetic information and passing it to new cells.

The Critical Link Between TUG1 and Replication Stress

New research has clarified how cancer cells cope with replication stress and the role of Taurine Upregulated Gene 1 (TUG1). Using a drug targeting TUG1, researchers controlled brain tumor growth in mice. This could be a potential strategy for fighting aggressive brain tumors such as glioblastoma.

Potential for Translation into Treatment

“These findings could translate into new drug applications because TUG1 is highly expressed in glioblastoma,” says Professor Yutaka Suzuki, lead investigator of the study published in Nature Communications.

The study successfully developed an experimental drug, TUG1-DDS, that selectively targets TUG1. The drug, particularly when given with standard temozolomide treatment, substantially suppressed tumor growth and improved the chances of survival.

How Cancer Cells Exploit DNA Replication

Cancer cells turn normal cellular processes to their advantage, creating an environment favorable to cancer cell growth. Even fundamental processes such as replication are exploited for cancer's benefit.

Replication Stress and Genomic Instability

Cancer cells improve conditions for themselves by disrupting the natural process of DNA replication. Each round of replication can normally involve errors such as breaks or mismatches. By manipulating DNA replication, cancer cells can create replication stress (RS). This stress breaks DNA strands and increases unpaired single-stranded DNA. The resulting genomic instability may support tumor growth.

One point is worth clarifying: replication stress is not triggered only by cancer cells. It can occur in normal cells too, but cancer cells may exploit it to their advantage.

Long Noncoding RNAs (lncRNA) and TUG1

Cancer cells use long noncoding RNAs (lncRNA) to repair their own DNA damage and remove unwanted R-loops. Researchers identified the role of the lncRNA TUG1.

1. Long Noncoding RNAs (lncRNA): These RNA molecules do not code for proteins but help regulate cellular processes.
2. Repairing Their Own DNA Damage and Removing R-loops: Cancer cells use lncRNAs to repair DNA damage and remove DNA:RNA hybrid structures called R-loops. R-loops can cause problems during DNA replication, making their control important.
3. The Role of lncRNA TUG1: Researchers discovered that a lncRNA called TUG1 plays an important role in this process. TUG1 works to repair DNA damage and control R-loops.
4. DHX9 and RPA32 Proteins: These two proteins work with the TUG1 lncRNA to suppress R-loops. Together, these three molecules can therefore control potentially harmful R-loops.

In summary, cancer cells use a lncRNA called TUG1 and the proteins DHX9 and RPA32 to repair DNA damage and remove R-loops. This mechanism helps them resolve problems that may arise during DNA replication.

Conclusion: Hope for Other Cancer Types Too

TUG1 inhibitors have also been found effective in other cancers, such as pancreatic and ovarian cancer. The new treatment candidate, TUG1-DDS, may therefore be effective in other cancer types expressing TUG1.

This study offers a potential treatment strategy for aggressive brain tumors and opens new horizons in cancer treatment.